The Dietary Inflammatory Index and Its Associations with Biomarkers of Nutrients with Antioxidant Potential, a Biomarker of Inflammation and Multiple Long-Term Conditions
2024 (English)In: Antioxidants, ISSN 2076-3921, Vol. 13, no 8, article id 962Article in journal (Refereed) Published
Abstract [en]
We aimed to validate the Dietary Inflammatory Index (DII®) and assess the cross-sectional associations between the DII® and multiple long-term conditions (MLTCs) and biomarker concentrations and MLTCs using data from the European Prospective Investigation into Cancer (EPIC-Norfolk) study (11,113 men and 13,408 women). The development of MLTCs is associated with low-grade chronic inflammation, and ten self-reported conditions were selected for our MLTC score. Data from a validated FFQ were used to calculate energy-adjusted DII® scores. High-sensitivity C-reactive protein (hs-CRP) and circulating vitamins A, C, E, β-carotene and magnesium were available. Micronutrient biomarker concentrations were significantly lower as the diet became more pro-inflammatory (p-trend < 0.001), and hs-CRP concentrations were significantly higher in men (p-trend = 0.006). A lower DII® (anti-inflammatory) score was associated with 12-40% higher odds of MLTCs. Lower concentrations of vitamin C and higher concentrations of hs-CRP were associated with higher odds of MLTCs. The majority of the associations in our study between MLTCs, nutritional biomarkers, hs-CRP and the DII® were as expected, indicating that the DII® score has criterion validity. Despite this, a more anti-inflammatory diet was associated with higher odds of MLTCs, which was unexpected. Future studies are required to better understand the associations between MLTCs and the DII®.
Place, publisher, year, edition, pages
MDPI, 2024. Vol. 13, no 8, article id 962
Keywords [en]
MLTCs, MM, antioxidant, biomarker, dietary inflammatory index, multi-morbidity, multiple long-term conditions, validation
National Category
Nutrition and Dietetics
Identifiers
URN: urn:nbn:se:oru:diva-115708DOI: 10.3390/antiox13080962ISI: 001307328500001PubMedID: 39199208Scopus ID: 2-s2.0-85202528658OAI: oai:DiVA.org:oru-115708DiVA, id: diva2:1894046
Note
The EPIC-Norfolk study (DOI: 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (G9502233, MR/N003284/1, MC-UU_12015/1 and MC_UU_00006/1) and Cancer Research UK (C864/A14136).
2024-09-022024-09-022025-02-11Bibliographically approved